
Soligenix SNGX
$ 1.13
-6.61%
Quarterly report 2025-Q3
added 11-07-2025
Soligenix P/S Ratio 2011-2026 | SNGX
Annual P/S Ratio Soligenix
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.73 | 5.84 | 2.14 | 18.1 | 10.3 | 2.26 | 2.51 | 0.846 | 2.62 | 3.37 | 11 | 5.84 | 1.14 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.1 | 0.846 | 5.51 |
P/S Ratio of other stocks in the Biotechnology industry
| Issuer | P/S Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.75 | - | 2.43 % | $ 254 M | ||
|
Verastem
VSTM
|
13.1 | $ 5.04 | -4.73 % | $ 349 M | ||
|
VistaGen Therapeutics
VTGN
|
151 | $ 0.57 | -5.87 % | $ 17.6 M | ||
|
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
0.099 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
489 | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
1.08 | - | 1.93 % | $ 17.4 M | ||
|
I-Mab
IMAB
|
94.1 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.96 K | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
13.3 | - | -0.23 % | $ 916 M | ||
|
Aptinyx
APTX
|
204 | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
137 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
105 K | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
11.2 | - | - | $ 7.46 M | ||
|
Acorda Therapeutics
ACOR
|
0.142 | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
2.27 | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
0.203 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.61 | - | - | - | ||
|
Avid Bioservices
CDMO
|
3.03 | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
25.8 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
8.96 | $ 12.41 | -11.1 % | $ 1.88 B | ||
|
BeiGene, Ltd.
BGNE
|
66.4 | - | 0.49 % | $ 251 B | ||
|
BioDelivery Sciences International
BDSI
|
1.85 | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
2.58 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
0.0564 | - | - | $ 3.74 B | ||
|
CureVac N.V.
CVAC
|
281 | - | - | $ 867 M | ||
|
Summit Therapeutics
SMMT
|
406 | $ 16.58 | -3.94 % | $ 12.4 B | ||
|
Zymeworks
ZYME
|
31.7 | $ 24.18 | -2.07 % | $ 1.25 B | ||
|
AbbVie
ABBV
|
24.1 | $ 209.4 | -0.83 % | $ 370 B | ||
|
AbCellera Biologics
ABCL
|
12.8 | $ 3.27 | -2.39 % | $ 977 M | ||
|
Altimmune
ALT
|
7.76 K | $ 3.02 | -5.63 % | $ 266 M | ||
|
Autolus Therapeutics plc
AUTL
|
1.37 K | $ 1.21 | -6.2 % | $ 309 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
11 | $ 317.36 | -3.29 % | $ 41.6 B | ||
|
Aytu BioScience
AYTU
|
0.237 | $ 2.6 | -2.8 % | $ 16.3 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
60.1 | $ 4.29 | -3.6 % | $ 822 M |